Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.67 |
| ▸ | TNF | P01375 | 9/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22272407 | 0.96 | PDE4D (0.62) | PDE4DTNFLRRK2EHMT2EHMT1 | |
| SCHEMBL22272372 | 0.89 | TNF (0.71) | PDE4DTNF | |
| SCHEMBL22272409 | 0.89 | TNF (0.71) | PDE4DTNF | |
| SCHEMBL20851820 | 0.82 | PDE4D (0.43) | PDE4DTNFEHMT2EHMT1PDE10A | |
| SCHEMBL22272374 | 0.82 | PDE4D (0.47) | PDE4DTNFLRRK2 | |
| SCHEMBL22272376 | 0.82 | PDE4D (0.57) | PDE4DTNFLRRK2 | |
| SCHEMBL22264615 | 0.79 | PDE4D (0.67) | PDE4DTNFLRRK2 | |
| SCHEMBL29735476 | 0.79 | PDE4D (0.67) | PDE4DTNFLRRK2 | |
| SCHEMBL22264614 | 0.79 | PDE4D (0.67) | PDE4DTNFLRRK2 | |
| SCHEMBL26968902 | 0.79 | PDE4D (0.42) | PDE4DTNFPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | PDE4D 11/4885TNF 969/4885LRRK2 1913/4885 |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | PDE4D 11/4885TNF 969/4885LRRK2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.